CITIUS PHARMACEUTICALS ($CTXR) is expected to release its quarterly earnings data on Friday, December 26th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.50 per share.
You can see Quiver Quantitative's $CTXR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CITIUS PHARMACEUTICALS Hedge Fund Activity
We have seen 16 institutional investors add shares of CITIUS PHARMACEUTICALS stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. removed 173,490 shares (-94.5%) from their portfolio in Q3 2025, for an estimated $215,127
- UBS GROUP AG removed 167,014 shares (-86.6%) from their portfolio in Q3 2025, for an estimated $207,097
- HEIGHTS CAPITAL MANAGEMENT, INC removed 159,898 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $198,273
- VANGUARD GROUP INC added 86,287 shares (+107.7%) to their portfolio in Q3 2025, for an estimated $106,995
- SQUAREPOINT OPS LLC removed 60,983 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $96,962
- GEODE CAPITAL MANAGEMENT, LLC added 43,676 shares (+57.4%) to their portfolio in Q3 2025, for an estimated $54,158
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 33,987 shares (+239.4%) to their portfolio in Q3 2025, for an estimated $42,143
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CITIUS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $CTXR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 08/13/2025
To track analyst ratings and price targets for CITIUS PHARMACEUTICALS, check out Quiver Quantitative's $CTXR forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
